Drug intelligence / Profile preview

dexfadrostat

Development stage: Phase 2
Lead developer: Damian Pharma
Modality: Small Molecules
Administration: Oral

Overview

Dexfadrostat is a potent nonsteroidal inhibitor of aldosterone synthase (CYP11B2), which is primarily used in treating primary aldosteronism (PA). It acts by inhibiting the production of aldosterone, thereby reducing blood pressure and correcting the aldosterone-to-renin ratio without affecting the adrenal stress response or the hypothalamic-pituitary-gonadal axis. Dexfadrostat is developed by Damian Pharma AG and has shown efficacy and safety in Phase 2 trials.

Other names: FadrozoleDP-13DP13DP 13

Targets

CYP19A1 (Aromatase)CYP11B2 (Cytochrome P450 11B2)

Beyond the preview

Go deeper on dexfadrostat.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on dexfadrostat.

Explore the full profile